Cargando…
Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
OBJECTIVE: To examine outcomes among patients who were treated with the targeted anti-cytokine agents, anakinra or tocilizumab, for COVID-19 -related cytokine storm (COVID19-CS). METHODS: We conducted a retrospective cohort study of all SARS-coV2-RNA-positive patients treated with tocilizumab or ana...
Autores principales: | Langer-Gould, Annette, Smith, Jessica B., Gonzales, Edlin G., Castillo, Rhina D., Figueroa, Judith Garza, Ramanathan, Anusha, Li, Bonnie H., Gould, Michael K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Southern California Permanente Medical Group. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406519/ https://www.ncbi.nlm.nih.gov/pubmed/32768693 http://dx.doi.org/10.1016/j.ijid.2020.07.081 |
Ejemplares similares
-
Intravenous anakinra for cytokine storm syndromes
por: Jamilloux, Yvan, et al.
Publicado: (2020) -
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
por: Smith, Jessica B., et al.
Publicado: (2022) -
Intravenous anakinra for cytokine storm syndromes – Authors' reply
por: Mehta, Puja, et al.
Publicado: (2020) -
Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023) -
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence
por: Langer-Gould, Annette M., et al.
Publicado: (2022)